Investment House LLC Purchases 640 Shares of Novartis AG (NYSE:NVS)
Investment House LLC raised its position in shares of Novartis AG (NYSE:NVS) by 0.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 83,946 shares of the company’s stock after purchasing an additional 640 shares during the period. Investment House LLC’s holdings in Novartis were worth $7,927,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in NVS. Verition Fund Management LLC bought a new position in Novartis during the second quarter valued at $234,000. Canada Pension Plan Investment Board bought a new position in Novartis during the second quarter valued at $4,382,000. Level Four Advisory Services LLC lifted its position in shares of Novartis by 7.3% during the second quarter. Level Four Advisory Services LLC now owns 4,365 shares of the company’s stock worth $380,000 after acquiring an additional 297 shares in the last quarter. Rockbridge Investment Management LCC purchased a new stake in shares of Novartis during the second quarter worth $25,000. Finally, Arvest Bank Trust Division purchased a new stake in shares of Novartis during the second quarter worth $217,000. 9.06% of the stock is owned by institutional investors and hedge funds.
Several equities research analysts have issued reports on the company. Morgan Stanley restated an “overweight” rating on shares of Novartis in a research report on Friday, January 8th. JPMorgan Chase & Co. restated an “underweight” rating on shares of Novartis in a research report on Tuesday, November 10th. Oddo Bhf downgraded Novartis from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 23rd. BidaskClub upgraded Novartis from a “hold” rating to a “buy” rating in a research report on Tuesday, January 5th. Finally, Argus increased their target price on Novartis from $100.00 to $112.00 in a research report on Thursday, December 3rd. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $114.00.
Novartis (NYSE:NVS) last issued its quarterly earnings data on Sunday, November 1st. The company reported $1.52 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.45 by $0.07. Novartis had a return on equity of 24.39% and a net margin of 14.71%. The company had revenue of $12.26 billion for the quarter, compared to the consensus estimate of $12.58 billion. During the same quarter last year, the business posted $1.41 earnings per share. The firm’s revenue was up .7% compared to the same quarter last year. Research analysts expect that Novartis AG will post 5.81 EPS for the current year.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Its Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, established, and cardiovascular, renal and metabolism medicine products.
See Also: What is a support level?
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.